GDF15 antagonism limits severe heart failure and prevents cardiac cachexia
- PMID: 39312445
- PMCID: PMC11687397
- DOI: 10.1093/cvr/cvae214
GDF15 antagonism limits severe heart failure and prevents cardiac cachexia
Abstract
Aims: Heart failure and associated cachexia is an unresolved and important problem. This study aimed to determine the factors that contribute to cardiac cachexia in a new model of heart failure in mice that lack the integrated stress response (ISR) induced eIF2α phosphatase, PPP1R15A.
Methods and results: Mice were irradiated and reconstituted with bone marrow cells. Mice lacking functional PPP1R15A, exhibited dilated cardiomyopathy and severe weight loss following irradiation, whilst wild-type mice were unaffected. This was associated with increased expression of Gdf15 in the heart and increased levels of GDF15 in circulation. We provide evidence that the blockade of GDF15 activity prevents cachexia and slows the progression of heart failure. We also show the relevance of GDF15 to lean mass and protein intake in patients with heart failure.
Conclusion: Our data suggest that cardiac stress mediates a GDF15-dependent pathway that drives weight loss and worsens cardiac function. Blockade of GDF15 could constitute a novel therapeutic option to limit cardiac cachexia and improve clinical outcomes in patients with severe systolic heart failure.
Keywords: Cachexia; GDF15; Heart failure; Integrated stress response; PPP1R15A.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Conflict of interest statement
Conflict of interest: S.O.R. is an employee of the University of Cambridge and has provided remunerated consultancy services to the following pharmaceutical companies with an active or potential interest in GDF15: Pfizer, AstraZeneca, MedImmune, and Novo-Nordisk. A.A.V. and J.T received consultancy fees and research support from Roche Diagnostics. The employer of AAV received consultancy fees and/or research support from AnaCardio, AstraZeneca, BMS, Boehringer Ingelheim, Bayer, Corteria, EliLilly, Moderna, Novartis, NovoNordisk, Roche Diagnostics.
Figures






References
-
- Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet 2019;393:1034–1044. - PubMed
-
- Sze S, Pellicori P, Kazmi S, Rigby A, Cleland JGF, Wong K, Clark AL. Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: a comparison with body mass index. JACC Heart Fail 2018;6:476–486. - PubMed
-
- Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, Luo X, Jiang N, May HI, Wang ZV, Hill TM, Mammen PPA, Huang J, Lee DI, Hahn VS, Sharma K, Kass DA, Lavandero S, Gillette TG, Hill JA. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 2019;568:351–356. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MR/V028669/1/MRC
- BRC-1215-20014/Cambridge Biomedical Research Centre
- RG90505/Victor Philip Dahdaleh Foundation
- RYC2020-028884-I/MCIN/AEI Ramon y Cajal
- FI17/00045/ISCIII P-FIS fellowship
- EP/R03558X/1/EPSRC
- G101517/BHF_/British Heart Foundation/United Kingdom
- 819775/ERC Consolidator Grant
- MR/Y011813/1/MRC_/Medical Research Council/United Kingdom
- Inserm, France
- MC_UU_0014/1/MRC Metabolic Diseases Unit
- ALUK
- NIHR203312/NIHR Cambridge Biomedical Research Centre
- 18/1/34212/Cambridge BHF Centre of Research Excellence
- MCMB MR/V028669/1/MRC_/Medical Research Council/United Kingdom
- MR/R009120/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources